Avelar Rui 4

What Happened Rui Avelar, Chief Medical Officer and Head of R&D at Evolus (EOLS), received three equity awards on February 17, 2026 totaling 328,475 units: 94,913 restricted stock units (RSUs), 94,913 performance-based restricted stock units (PSUs), and 138,649 option-based awards. All grants are reported at $0.00 (no cash was paid at grant). These awards are compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (timely).
• Grants: 94,913 RSUs (F1); 94,913 PSUs (F2/F3); 138,649 option-based awards (F4).
• Price shown: $0.00 for all items — reflects a grant/award, not a paid purchase.
• Vesting/performance notes:
  • RSUs vest in four equal annual installments on each anniversary of Feb 17, 2026, subject to service and possible acceleration (F1).
  • PSUs pay 0–200% of target based on pre-established financial metrics and relative TSR over a three‑year performance period ending Dec 31, 2028; any earned PSUs vest after certification of results (F2, F3).
  • Option-based awards vest in four equal annual installments on each anniversary of Feb 17, 2026, subject to service and possible acceleration (F4).
• Shares owned after the transaction: not reported in the filing.

Context These entries are awards/compensation (transaction code A) rather than open-market trades. PSUs are performance-contingent — the actual number of shares delivered could be up to 200% of target depending on performance and certification. The filing does not indicate any immediate sale or cashless exercise; this is a forward-looking compensation grant that vests over time or upon achievement of performance goals.